CDK4 and liposarcoma: The efficacy of CDK4 inhibitors such as palbociclib and abemaciclib in advanced liposarcoma with MDM2/CDK4 amplification is modest in early trials and real-world settings,4-6 suggesting a cytostatic rather than cytotoxic effect.